TMO vs QGEN vs DHR Stock Comparison

Thermo Fisher Scientific, Qiagen and Danaher Prices as of Nov 13, 2026 Peers: Industry group
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.82B
P/E
28.1x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
DHR Danaher Corp /De/
$233.03 +3.7% 1M +5.3% 1Y
Market cap
$163.02B
P/E
37.6x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare

Head to Head

11 decided of 12

Thermo Fisher Scientific leads on 6 of the 12 questions below (Thermo Fisher Scientific 6, Qiagen 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOQGENDHRLeader
Larger companyMarket capitalisation $256.90B $10.82B $163.02B TMO
Cheaper on earningsLower P/E, profitable companies only 36.3x 28.1x 37.6x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.0x 21.2x 25.6x QGEN
Faster revenue growthRevenue growth, trailing twelve months +8.3% +2.2% +5.5% TMO
More profitableNet margin, trailing twelve months 14.9% 18.2% 16.9% QGEN
Better return on capitalReturn on invested capital 8.0% 7.4% 5.8% TMO
Less leveragedLower net debt / EBITDA 3.1x 1.2x 2.6x QGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +20.7% +6.2% +5.3% TMO
Better 5-year returnAnnualised price return, 5 years +2.0%/yr -3.6%/yr -5.2%/yr TMO
Less volatileAnnualised volatility, 1 year 30.7% 35.2% 31.0% TMO
Higher overall scoreMean of the five percentile scores vs peers 60/100 69/100 60/100 QGEN

Percentile Scorecard

TMOQGENDHR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOQGENDHR
Valuation 62 #94 of 243 74 #63 of 243 69 #76 of 243
Growth 41 #136 of 228 25 #171 of 228 25 #172 of 228
Profitability 82 #40 of 222 93 #16 of 222 86 #32 of 222
Financial Health 31 #172 of 248 60 #100 of 248 47 #133 of 248
Shareholder Returns 82 #29 of 158 94 #11 of 158 73 #44 of 158
Overall 60 69 60
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics
  • DHR ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOQGENDHRSPY
1 month +4.0%+9.6%+3.7% -2.0%
3 months +19.1%+16.2%+15.1% -2.8%
6 months +59.7%+51.3%+43.9% +2.0%
Year to date +20.8%+5.4%+1.8% +10.6%
1 year +20.7%+6.2%+5.3% +12.2%
3 years +52.5%+13.0%+14.5% +68.1%
3 years, per year +15.1%+4.2%+4.6% +18.9%
5 years +10.2%-16.9%-23.4% +61.4%
5 years, per year +2.0%-3.6%-5.2% +10.1%
10 years +362.9%+56.5%+187.9% +248.5%
10 years, per year +16.6%+4.6%+11.2% +13.3%

Risk

MeasureTMOQGENDHRSPY
Volatility, 1Y 30.7%35.2%31.0% 13.6%
Downside volatility, 1Y 29.2%29.7%32.4% 13.9%
Beta vs S&P 500, 1Y 0.710.380.55 1.00
Return / volatility, 1Y 0.670.180.17 0.90
Max drawdown, 5Y -41.5%-48.2%-50.8% -25.4%
From 52-week high -3.0%-10.3%-3.7% -3.2%
52-week high $721.63$55.66$242.05 $779.14
52-week low $438.34$32.63$161.91 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOQGENDHR
P/E now vs peer median 36.6xmedian 26.5x 28.2xmedian 26.5x 37.9xmedian 26.5x
P/S now vs peer median 5.5xmedian 2.7x 5.1xmedian 2.7x 6.4xmedian 2.7x
EV/EBITDA now vs peer median 25.5xmedian 18.4x 17.7xmedian 18.4x 23.5xmedian 18.4x
P/FCF now vs peer median 34.2xmedian 25.4x 11.2xmedian 25.4x 28.6xmedian 25.4x
P/B now vs peer median 4.7xmedian 2.5x 3.1xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 4.84median 0.98 11.74median 0.98 -4.72median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOQGENDHR
Revenue $47.35B $2.12B $25.61B
Gross profit $19.45B $1.33B $15.01B
Operating income $8.47B $448.74M $5.22B
Net income $7.09B $384.93M $4.33B
Free cash flow $7.60B $964.47M $5.73B
R&D $1.40B $199.87M $1.67B
EPS (diluted) $19.06 $1.76 $6.13
Cash & equivalents $5.46B $805.13M $5.68B
Total debt $41.37B $1.64B $26.48B
Shares (diluted) 371.00M 218.88M 706.80M
Enterprise value $233.42B $7.46B $142.67B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOQGENDHR
P/E 36.6x 28.2x 37.9x
P/FCF 34.2x 11.2x 28.6x
P/Operating cash flow 27.8x 17.0x 23.9x
P/S 5.5x 5.1x 6.4x
P/B 4.7x 3.1x 3.1x
P/Tangible book 7.1x 3.4x 5.0x
EV/EBITDA 25.5x 17.7x 23.5x
EV/EBIT 34.8x 25.9x 35.4x
EV/Revenue 6.2x 5.5x 7.2x
EV/FCF 38.8x 12.1x 32.3x
EV/Operating cash flow 31.6x 18.3x 26.9x
PEG (3Y EPS CAGR) 4.84 11.74 -4.72

Growth

14 metrics
MetricTMOQGENDHR
Revenue growth (1Y) 8.3% 2.2% 5.5%
Revenue CAGR (3Y) 2.9% 2.7% 1.3%
Gross profit growth (1Y) 7.8% 1.7% 3.9%
Gross profit CAGR (3Y) 4.0% 2.5% 1.2%
Operating income growth (1Y) 12.8% -7.6% 13.1%
Operating income CAGR (3Y) 7.2% 3.6% -3.8%
Net income growth (1Y) 7.9% -2.8% 23.6%
Net income CAGR (3Y) 6.2% 5.0% -9.9%
EPS growth (1Y) 9.7% -7.3% 24.8%
EPS CAGR (3Y) 7.6% 2.4% -8.0%
Operating cash flow growth (1Y) 21.9% -3.4% 8.6%
Operating cash flow CAGR (3Y) 4.5% 13.7% -5.3%
Free cash flow growth (1Y) 24.3% 1.1% 14.2%
Free cash flow CAGR (3Y) 5.1% 13.5% -5.8%

Profitability

14 metrics
MetricTMOQGENDHR
Gross margin 41.1% 62.8% 58.6%
EBITDA margin 24.4% 31.0% 30.7%
Operating margin 17.9% 21.2% 20.4%
Pretax margin 16.7% 21.7% 18.8%
Net margin 14.9% 18.2% 16.9%
FCF margin 16.0% 45.6% 22.4%
Operating cash flow margin 19.7% 30.0% 26.8%
Return on equity 13.2% 11.3% 8.2%
Return on assets 6.2% 6.5% 4.7%
Return on invested capital 8.0% 7.4% 5.8%
Return on capital employed 8.5% 8.5% 6.2%
Asset turnover 0.4x 0.4x 0.3x
Cash conversion (OCF / net income) 1.3x 1.6x 1.6x
Stock comp / revenue 0.7% 2.0% 1.3%

Financial Health

11 metrics
MetricTMOQGENDHR
Debt / assets 36.2% 27.6% 28.4%
Debt / equity 0.8x 0.5x 0.5x
Net debt / EBITDA 3.1x 1.2x 2.6x
Debt / FCF 5.4x 1.7x 4.6x
Liabilities / assets 52.1% 41.5% 42.5%
Equity / assets 47.9% 58.5% 57.5%
Interest coverage 12.0x 10.8x 14.5x
Current ratio 1.8x 2.6x 1.6x
Quick ratio 1.2x 1.9x 1.1x
Cash ratio 0.4x 1.3x 0.6x
Altman Z-score 4.18 4.14 3.75

Shareholder Returns

7 metrics
MetricTMOQGENDHR
Dividend yield 0.3% 5.3% 0.7%
Net buyback yield 1.6% 0.6% 0.5%
Shareholder yield 1.8% 5.9% 1.1%
Payout ratio (earnings) 9.5% – –
Payout ratio (FCF) 8.9% – –
Dividend growth (1Y) 8.0% – –
Dividend CAGR (3Y) 10.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOQGENDHR
Forward P/E 27.0xFY2026 21.2xFY2026 25.6xFY2026
EPS, next fiscal year $25.92FY2026 $2.35FY2026 $9.12FY2026
EPS growth, next FY +13.3%FY2026 -1.3%FY2026 +16.9%FY2026
EPS growth, the year after +2.2% +17.9% +7.9%
Revenue, next fiscal year $50.12BFY2026 $2.25BFY2026 $27.01BFY2026
Revenue growth, next FY +12.5%FY2026 +7.8%FY2026 +9.9%FY2026
Revenue growth, the year after -2.7% -2.8% -1.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOQGENDHR
Held by institutions 90.2% 67.3% 81.9%
Institutions holding 2,627 338 2,121
Change in shares held, QoQ +0.8% +16.5% +1.1%
Institutions buying 1,145 216 841
Institutions selling 1,145 86 1,016
Buyers to sellers 1.00 2.51 0.83

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOQGENDHR
TMO 1.00 0.44 0.73
QGEN 0.44 1.00 0.37
DHR 0.73 0.37 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, QGEN and DHR?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $256.90B, Qiagen (QGEN) $10.82B, Danaher (DHR) $163.02B.

Which stock is cheaper, TMO, QGEN and DHR?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.3x, Qiagen (QGEN) 28.1x, Danaher (DHR) 37.6x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Qiagen (QGEN) 21.2x, Danaher (DHR) 25.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Qiagen (QGEN) +2.2%, Danaher (DHR) +5.5%.

Which company is more profitable?

Qiagen (QGEN) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Qiagen (QGEN) 18.2%, Danaher (DHR) 16.9%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Thermo Fisher Scientific (TMO) 8.0%, Qiagen (QGEN) 7.4%, Danaher (DHR) 5.8%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Thermo Fisher Scientific (TMO) +20.7%, Qiagen (QGEN) +6.2%, Danaher (DHR) +5.3%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Qiagen (QGEN) -3.6%/yr, Danaher (DHR) -5.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Thermo Fisher Scientific (TMO) 0.00%, Qiagen (QGEN) 0.00%, Danaher (DHR) 0.00%. Qiagen (QGEN) and Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Thermo Fisher Scientific (TMO) 30.7%, Qiagen (QGEN) 35.2%, Danaher (DHR) 31.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, QGEN and DHR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.